Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Incannex Healthcare (IXHL) Research & Development (2023 - 2025)

Historic Research & Development for Incannex Healthcare (IXHL) over the last 3 years, with Q4 2025 value amounting to -$2.3 million.

  • Incannex Healthcare's Research & Development fell 6124.47% to -$2.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $5.3 million, marking a year-over-year decrease of 4212.55%. This contributed to the annual value of $10.7 million for FY2025, which is 1655.41% down from last year.
  • Latest data reveals that Incannex Healthcare reported Research & Development of -$2.3 million as of Q4 2025, which was down 6124.47% from $1.1 million recorded in Q3 2025.
  • In the past 5 years, Incannex Healthcare's Research & Development registered a high of $4.4 million during Q2 2024, and its lowest value of -$2.3 million during Q4 2025.
  • For the 3-year period, Incannex Healthcare's Research & Development averaged around $2.0 million, with its median value being $2.7 million (2023).
  • Data for Incannex Healthcare's Research & Development shows a peak YoY increase of 1104.29% (in 2024) and a maximum YoY decrease of 15360.12% (in 2024) over the last 5 years.
  • Over the past 3 years, Incannex Healthcare's Research & Development (Quarter) stood at $2.6 million in 2023, then crashed by 153.6% to -$1.4 million in 2024, then crashed by 61.24% to -$2.3 million in 2025.
  • Its last three reported values are -$2.3 million in Q4 2025, $1.1 million for Q3 2025, and $3.7 million during Q2 2025.